Familial melanoma genes, melanocyte immortalization, and melanoma initiation

From Melanocytes to Melanoma: The Progression to Malignancy

Volumn , Issue , 2006, Pages 183-196

  Bennett, Dorothy C ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

apoptosis; CDKN2A; cell senescence; immortalization; Melanoma; nevus; p16; RB1; telomere

Indexed keywords

EID: 33747161408     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59259-994-3_10     Document Type: Chapter

References (90)

1. Arends JW. Molecular interactions in the Vogelstein model of colorectal carcinoma. J Pathol 2000;190:412-416.
2. Cook PJ, Doll R, Fellingham SA. A mathematical model for the age distribution of cancer in man. Int J Cancer 1969;4:93-112.
3. Clark WH, Elder DE, Guerry D, Epstein MN, Greeve MH, Van Horn M. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 1984;15: 1147-1165.
4. Clark WH, Elder DE, Guerry D, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989;81:1893-1904.
5. Crotty K, McCarthy S, Mihm MC. The histological diagnosis and classification of melanoma. In: Thompson JF, Morton DL, Kroon BBR, eds. Textbook of melanoma. Martin Dunitz, New York, NY: 2004, pp. 115-121.
6. Wynford-Thomas D. Cellular senescence and cancer. J Pathol 1999;187:100-111.
7. Newbold RF. The significance of telomerase activation and cellular immortalization in human cancer. Mutagenesis 2002;17:539-550.
8. Sharpless NE, DePinho RA. Telomeres, stem cells, senescence, and cancer. J Clin Invest 2004;113:160-168.
9. Bennett DC, Medrano EE. Molecular regulation of melanocyte senescence. Pigment Cell Res 2002;15:242-250.
10. Bennett DC. Human melanocyte senescence and melanoma susceptibility genes. Oncogene 2003;22:3063-3069.
11. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965;37:614-636.
12. Bond JA, Haughton MF, Rowson JM, et al. Control of replicative life span in human cells: barriers to clonal expansion intermediate between M1 senescence and M2 crisis. Mol Cell Biol 1999;19: 3103-3114.
13. Blackburn EH. Telomere states and cell fates. Nature 2000;408:53-56.
14. Stewart SA, Ben Porath I, Carey VJ, O'Connor BF, Hahn WC, Weinberg RA. Erosion of the telomeric single-strand overhang at replicative senescence. Nat Genet 2003;33:492-496.
15. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003; 426: 194-198.
16. Ramirez RD, Herbert BS, Vaughan MB, et al. Bypass of telomere-dependent replicative senescence (M1). upon overexpression of Cdk4 in normal human epithelial cells. Oncogene 2003;22:433-444.
17. INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 1997;15:203-211.
18. Hara E, Smith R, Parry D, Tahara H, Stone S, Peters G. Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol 1996;16:859-867.
19. INK4a expression during cellular senescence. Nature 2001;409:1067-1070.
20. INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 1998;396:84-88.
21. Ramirez RD, Morales CP, Herbert BS, et al. Putative telomere-independent mechanisms of replicative aging reflect inadequate growth conditions. Genes Dev 2001;15:398-403.
22. Bandyopadhyay D, Medrano EE. Melanin accumulation accelerates melanocyte senescence by a mechanism involving p16{+INK4a}/CDK4/pRB and E2F1. Ann N Y Acad Sci 2000;908:71-84.
23. Sviderskaya EV, Gray-Schopfer VC, Hill SP, et al. p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: possible implications for melanoma progression. J Natl Cancer Inst 2003;95:723-732.
24. Itahana K, Zou Y, Itahana Y, et al. Control of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1. Mol Cell Biol 2003;23:389-401.
25. Gray-Schopfer VC, Cheong SC, Chow J, et al. Cellular senescence in melanocytic nevi: a mechanism for melanoma suppression by p16. 2005, submitted.
26. Hayward NK. Genetics of melanoma predisposition. Oncogene 2003;22:3053-3062.
27. Kefford RF, Mann GJ, Newton Bishop J. Genetic predisposition to melanoma. In: Thompson JF, Morton DL, Kroon BBR, eds. Textbook of Melanoma. Martin Dunitz, New York, NY: 2004, pp. 56-64.
28. Gray-Schopfer VC, Bennett DC. The genetics of melanoma. In: Nordlund JJ, Boissy RE, Hearing VJ, King RA, Oetting WS, Ortonne JP, eds. The Pigmentary System. Physiology and Pathophysiology. Oxford University Press, New York, NY: 2005, in press.
29. Gillanders E, Juo SH, Holland EA, et al. Localization of a novel melanoma susceptibility locus to 1p22. Am J Hum Genet 2003;73:301-313.
30. INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996;12:97-99.
31. Soufir N, Avril MF, Chompret A, et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 1998;7:209-216.
32. Hayward N. New developments in melanoma genetics. Curr Oncol Rep 2000;2:300-306.
33. Tucker MA, Goldstein AM. Melanoma etiology: where are we? Oncogene 2003;22:3042-3052.
34. Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1998;1378:F115-F177.
35. Sherr CJ. The INK4a/ARF network in tumour suppression. Nature Rev Mol Cell Biol 2001;2:731-737.
36. Sharpless NE, DePinho RA. The INK4A/ARF locus and its two gene products. Curr Opinion Genet Dev 1999;9:22-30.
37. Rizos H, Puig S, Badenas C, et al. A melanoma-associated germline mutation in exon 1beta inactivates p14ARF. Oncogene 2001;20:5543-5547.
38. Randerson-Moor JA, Harland M, Williams S, et al. A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet 2001;10:55-62.
39. Hewitt C, Lee WC, Evans G, et al. Germline mutation of ARF in a melanoma kindred. Hum Mol Genet 2002;11(11):1273-1279.
40. ARF, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998;92:713-723.
41. Momand J, Wu HH, Dasgupta G. MDM2-master regulator of the p53 tumor suppressor protein. Gene 2000;242:15-29.
42. Kamijo T, Zindy F, Roussel MF, et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997;91:649-659.
43. ARF in replicative and induced senescence of human fibroblasts. Mol Cell Biol 2001;21:6748-6757.
44. Hsieh JK, Chan FSG, O'Connor DJ, Mittnacht S, Zhong S, Lu X. RB regulates the stability and the apoptotic function of p53 via MDM2. Mol Cell 1999;3:181-193.
45. INK4a. Cell 1997;88:593-602.
46. Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M, Lowe SW. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev 1998;12:3008-3019.
47. Drayton S, Rowe J, Jones R, et al. Tumor suppressor p16INK4a determines sensitivity of human cells to transformation by cooperating cellular oncogenes. Cancer Cell 2003;4:301-310.
48. Serrano M, Lee HW, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996;85:27-37.
49. Ink4a in melanocyte senescence and differentiation. J Natl Cancer Inst 2002;94:446-454.
50. Gruis NA, van der Velden PA, Sandkuijl LA, et al. Homozygotes for CDKN2 (p1) germline mutation in Dutch familial melanoma kindreds. Nat Genet 1995;10:351-353.
51. INK4a confer resistance to Ras-and Ets-induced senescence in human diploid fibroblasts. Mol Cell Biol 2002;22:8135-8143.
52. Ink4a confers susceptibility to metastatic melanoma in mice. Nature 2001;413:83-86.
53. Ink4a in mouse melanocyte senescence. Pigment Cell Res 2004;17:568.
54. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003;33:19-20.
55. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 2003;9:6483-6488.
56. Yazdi AS, Palmedo G, Flaig MJ, et al. Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol 2003;121:1160-1162.
57. Wellbrock C, Ogilvie L, Hedley D, et al. V599EB-RAF is an oncogene in melanocytes. Cancer Res 2004;64(7):2338-2342.
58. Mooi WJ, Peeper DS. Pathogenesis of melanocytic naevi: growth arrest linked with cellular senescence? Histopathol 2002;41:120-146.
59. Bastian BC. The longer your telomeres, the larger your nevus? Am J Dermatopathol 2003;25:83-84.
60. Healy E, Belgaid C, Takata M, et al. Prognostic significance of allelic losses in primary melanoma. Oncogene 1998;16:2213-2218.
61. Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995;92:9363-9367.
62. Talve L, Sauroja I, Collan Y, Punnonen K, Ekfors T. Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage. Int J Cancer 1997;74:255-259.
63. INK4 in benign and malignant melanocytic lesions. J Invest Dermatol 1998;110:932-938.
64. Park WS, Vortmeyer AO, Pack S, et al. Allelic deletion at chromosome 9p21(p16) and 17p13(p53) in microdissected sporadic dysplastic nevus. Hum Pathol 1998;29(2):127-130.
65. Papp T, Pemsel H, Rollwitz I, et al. Mutational analysis of N-ras, p53, CDKN2A (p16(INK4a)), p14(ARF), CDK4, and MC1R genes in human dysplastic melanocytic naevi. J Med Genet 2003;40:E14.
66. Londono-Vallejo JA, Der-Sarkissian H, Cazes L, Bacchetti S, Reddel RR. Alternative lengthening of telomeres is characterized by high rates of telomeric exchange. Cancer Res 2004;64:2324-2327.
67. Ramirez RD, D'Atri S, Pagani E, et al. Progressive increase in telomerase activity from benign melanocytic conditions to malignant melanoma. Neoplasia 1999;1:42-49.
68. Glaessl A, Bosserhoff AK, Buettner R, Hohenleutner U, Landthaler M, Stolz W. Increase in telomerase activity during progression of melanocytic cells from melanocytic naevi to malignant melanomas. Arch Dermatol Res 1999;291:81-87.
69. Rudolph P, Schubert C, Tamm S, et al. Telomerase activity in melanocytic lesions: a potential marker of tumor biology. Am J Pathol 2000;156:1425-1432.
70. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954.
71. Straume O, Sviland L, Akslen LA. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res 2000;6:1845-1853.
72. Pavey SJ, Cummings MC, Whiteman DC, et al. Loss of p16 expression is associated with histological features of melanoma invasion. Melanoma Res 2002;12:539-547.
73. Bartkova J, Lukas J, Guldberg P, et al. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 1996;56:5475-5483.
74. Herlyn M, Thurin J, Balaban G, et al. Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res 1985;45:5670-5676.
75. Herlyn M, Balaban G, Bennicelli J, et al. Primary melanoma cells of the vertical growth phase: similarities to metastatic cells. J Natl Cancer Inst 1985;74:283-289.
76. Albino AP, Vidal MJ, McNutt NS, et al. Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res 1994;4:35-45.
77. Castellano M, Parmiani G. Genes involved in melanoma: an overview of INK4a and other loci. Melanoma Res 1999;9:421-432.
78. Soengas MS, Capodieci P, Polsky D, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001;409:207-211.
79. Baldi A, Santini D, Russo P, et al. Analysis of APAF-1 expression in human cutaneous melanoma progression. Exp Dermatol 2004;13:93-97.
80. Easty DJ, Bennett DC. Protein tyrosine kinases in malignant melanoma. Melanoma Res 2000; 10:401-411.
81. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001;411:355-365.
82. Guldberg P, Thor SP, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 1997;57: 3660-3663.
83. Pollock PM, Walker GJ, Glendening JM, et al. PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines. Melanoma Res 2002;12:565-575.
84. Plettenberg A, Ballaun C, Pammer J, et al. Human melanocytes and melanoma cells constitutively express the Bcl-2 proto-oncogene in situ and in cell culture. Am J Pathol 1995;146:651-659.
85. Yamamura K, Kamada S, Ito S, Nakagawa K, Ichihashi M, Tsujimoto Y. Accelerated disappearance of melanocytes in bcl-2-deficient mice. Cancer Res 1996;56:3546-3550.
86. Bush JA, Li G. The role of Bcl-2 family members in the progression of cutaneous melanoma. Clin Exp Metastasis 2003;20:531-539.
87. Omholt K, Platz A, Ringborg U, Hansson J. Cytoplasmic and nuclear accumulation of beta-catenin is rarely caused by CTNNB1 exon 3 mutations in cutaneous malignant melanoma. Int J Cancer 2001;92:839-842.
88. Worm J, Christensen C, Gronbaek K, Tulchinsky E, Guldberg P. Genetic and epigenetic alterations of the APC gene in malignant melanoma. Oncogene 2004;23:5215-5226.
89. Chen D, Xu W, Bales E, et al. SKI activates Wnt/beta-catenin signaling in human melanoma. Cancer Res 2003;63:6626-6634.
90. Bell DW, Varley JM, Szydlo TE, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999;286:2528-2531.